The CBR-IC2/2 monoclonal antibody specifically binds to CD102 which is also known as, intercellular adhesion molecule-2 (ICAM-2/ICAM2). CD102 is a type I transmembrane glycoprotein, member of the immunoglobulin supergene family, with an approximate molecular weight of 55-65 kDa. Its extracellular domain consists of two C2-type immunoglobulin-like subunits. The transmembrane region is 26 residues in size and the intracellular region also has 26 residues. CD102 is expressed on vascular endothelial cells, lymphocytes, monocytes, eosinophils, and platelets, but not on resting neutrophils. It is a ligand for the leukocyte integrin CD11a/CD18, or leukocyte function-associated antigen-1 (LFA-1), and there are reports of CD102 binding to leukocyte integrin CD11b/CD18 (Mac-1). Antibody CBR-IC2/2 blocks the binding of CD102 to leukocyte integrin CD11a/CD18. CD102 plays an important role in lymphocyte recirculation and in providing costimulatory signals in the immune response.
The antibody was conjugated to BD Horizon™ BUV496 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome of BD Horizon BUV395 with an Ex Max of 348-nm and an acceptor dye with an Em Max at 496-nm. BD Horizon BUV496 can be excited by the ultraviolet laser (355 nm) and detected with a 515/30 nm filter with a 450LP. Due to the excitation of the acceptor dye by other laser lines, there may be significant spillover into the channel detecting BD Horizon V500 or BV510 (eg, 525/40-nm filter). However, the spillover can be corrected through compensation as with any other dye combination.